This phase III trial compares the effects of robot-assisted radical prostatectomy (RARP) with or without vesicopexy on urinary continence (a person's ability to control their bladder) and quality of life in patients with cancer of the prostate. RARP is the most adopted surgical approach for treatment of prostate cancer that has not spread to other places in the body (non-metastatic). Urinary incontinence (inability to control the bladder) is one of the most common complications of RARP, impacting patients' quality of life and psychological well-being. Different techniques have been proposed to improve urinary continence following RARP. Vesicopexy is one technique that restores the bladder to its normal position in the body after RARP. This study aims to evaluate whether RARP with vesicopexy may improve urinary continence and quality of life after surgery in prostate cancer patients.
PRIMARY OBJECTIVE: I. To determine the 3-month (+/- 3 weeks) urinary continence following RARP with or without vesicopexy. SECONDARY OBJECTIVES: I. To evaluate the 3-month (+/- 3 weeks) quality of life following RARP with or without vesicopexy. II. To evaluate the 72-hour post-operative (postop) urinary continence following RARP with or without vesicopexy. III. To evaluate the 1-month (+/- 1 week) postop urinary continence following RARP with or without vesicopexy. IV. To evaluate sexual function at 3-month (+/- 3 weeks) following RARP with or without vesicopexy. V. To evaluate the operative time in patients undergoing RARP with or without vesicopexy. VI. To evaluate intraoperative complications in patients undergoing RARP with or without vesicopexy. VII. To evaluate 90-day post-operative complications in patients undergoing RARP with or without vesicopexy. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo standard RARP with anterior approach plus vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion. ARM II: Patients undergo standard RARP with anterior approach without vesicopexy. Urethral catheters are removed 7-14 days following surgery at provider discretion. After study completion, patients will be followed-up with at 24 hours, 1-month, and 3-months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
196
Ancillary studies
Ancillary studies
Undergo RARP
Undergo vesicopexy
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
3-month (+/- 3 weeks) urinary continence rate following RARP with or without vesicopexy
Defined continence as 0-1 safety pad usage. Use the "pictorial pad usage questionnaire."
Time frame: 3 months post-operative
3-month (+/- 3 weeks) quality of life following surgery
Use the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ-PR25).
Time frame: 3 months post-operative
72-hour postop urinary continence following surgery
Defined continence as 0-1 safety pad usage. Assessed with the "pictorial pad usage questionnaire."
Time frame: 72 hours post-operative
1-month (+/- 1 week) post-operative urinary continence following surgery
Defined continence as 0-1 safety pad usage. Assessed with the "pictorial pad usage questionnaire."
Time frame: 1 month post-operative
Sexual function at 3-month (+/- 3 weeks) following surgery
Sexual Health Inventory for Men (SHIM) questionnaire is used for the evaluation of sexual function.
Time frame: 3 months post-operative
Operative time
Time frame: Duration of operation
Intra-operative complications
Time frame: Duration of operation
90-day post-operative complications
Time frame: 90 days post-operative
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.